Trastuzumab and retifanlimab for early HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of two drugs—trastuzumab, a standard targeted therapy, and retifanlimab, an immunotherapy—for people with early-stage HER2-positive breast cancer. The goal is to see if adding immunotherapy before surgery can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with HER2-positive breast cancer (a specific protein that helps cancer grow).
- Your tumor is between 1 and 5 centimeters in size and has not spread to many lymph nodes.
- Your heart function is normal (measured by an echocardiogram or similar test).
- You are generally in good health (able to do your daily activities, with a performance status of 0 or 1).
- You are willing to provide biopsy samples and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This trial tests a new antibody-drug combination (trastuzumab rezetecan, also called T-DXd) for patients with HER2-positive breast cancer whose tumor did not fully disappear after initial chemotherapy. The goal is to see if this drug can reduce the risk of cancer coming back.
This trial tests a combination of two drugs (trastuzumab rezetecan and toripalimab) given before surgery to treat a specific type of breast cancer that is hormone-receptor-positive and HER2-low. It aims to see if this treatment can improve outcomes for patients who have not had prior cancer treatment.
This trial tests a new drug, Trastuzumab-rezetecan, in people with breast cancer that has a certain amount of a protein called HER2. It aims to see if the drug works and is safe for patients who are able to receive it before or after surgery, or for those whose cancer has spread and has been treated before.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial tests a combination of targeted therapies and hormone therapy for early-stage breast cancer that is HER2-positive and hormone receptor-positive. The goal is to see if this treatment can help shrink the tumor before surgery.
Hear when a new HER2-addicted Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.